Degron Therapeutics Participated at UBS Virtual Targeted Protein Degradation Day

Shanghai, China and San Diego, CA, July 15th, 2024, Degron Therapeutics Inc. CEO & Co-founder, Lily Zou, PhD, participated in a fireside chat at the Virtual Targeted Protein Degradation (TPD) Day hosted by the Swiss investment bank UBS.

Leading players in the TPD field, including public and private companies Arvinas (ARVN), Bristol Myers Squibb (BMY), C4 Therapeutics (CCCC), Monte Rosa Therapeutics (GLUE), Kymera Therapeutics (KYMR), Nurix Therapeutics (NRIX), Degron Therapeutics, Casma Therapeutics, and TRIANA Biomedicines, were invited to fireside chats and 1x1s at this event. A breakthrough in drug development, TPD offers a new tool in biotech and pharma’s toolkit, to develop drugs for traditionally difficult-to-target areas. The clinical data from several companies’ pipelines suggest exciting potential for the field.

As one of the global leaders in the molecular glue degrader space, Degron has established a discovery platform (GlueXplorer^®) including a proprietary compound library with unique scaffolds in differentiated chemical space, and rapidly expanding databases of a variety of activity measures of its compounds. The company is focused on using its differentiated platform to discover and develop molecular glue degraders for novel targets, with a target selection strategy focusing on disease drivers that are unable to be adequately drugged by other mechanisms including PROTACs and small molecule inhibitors.

Degron announced in May 2024 a collaboration with Takeda with potential value up to $1.2 billion including an upfront payment and potential milestones and royalties, focusing on oncology, neuroscience, and inflammation.

About Degron Therapeutics

Degron Therapeutics uses its molecular glue-based targeted protein degradation drug discovery platform to develop novel medicines and advance human health. The company’s unique GlueXplorer^® platform encompasses a rapidly expanding IP-protected compound library and screening systems to develop a new class of small-molecule medicines that target important disease targets, including those previously undruggable. The company’s pipeline comprises a growing number of preclinical programs for oncology, inflammation, metabolic disorders, and rare diseases. For more information, please visit www.degrontx.com.